BACKGROUND: Pandemic H1N1 (pH1N1) surveillance data showed lower attack rates but higher risk of severe outcomes with advanced age. We explored immuno-epidemiologic correlates of surveillance findings including humoral and cell-mediated immunity (CMI). METHODS: In an age-based design, ∼100 banked/residual sera per 10-year age stratum were assessed by hemagglutination inhibition (HI) and microneutralization (MN) assays for preexisting antibody to pH1N1 and recent seasonal H1N1 and H3N2 strains. In a separate birth cohort design defined by childhood influenza A/subtype priming (1919-1929: H1N1; 1945-1949: H1N1; 1958-1960: H2N2; 1969-1970: H3N2; 1978-1989: H3N2/H1N1), whole blood was collected from up to 50 volunteers per birth cohort. The ratio of Th1(IFN-γ):Th2(IL-10) cytokine responses was evaluated in vitro. RESULTS: Antibody to seasonal viruses was highest in school-age children. Cross-reactive HI/MN antibody to pH1N1 was low among participants <70 years of age (yoa; 6%/4% ≥ 40), but seroprevalence increased at 70-79 yoa (27%/6%), increased even more at 80-89 yoa (65%/47%), and was highest at ≥90 yoa (88%/76%). CMI to pH1N1 was evident in all 5 birth cohorts but was lower compared with seasonal strains. There was little differentiation by subtype priming, but the Th1:Th2 ratio for all viruses dropped significantly in the 2 oldest cohorts. CONCLUSIONS: Preexisting antibody may have protected the very old from pH1N1 infection, while diminished CMI may have contributed to greater severity once infected. In the young, cross-reactive pH1N1 antibody was mostly absent, while more intact CMI may have protected against severe outcomes.
BACKGROUND: Pandemic H1N1 (pH1N1) surveillance data showed lower attack rates but higher risk of severe outcomes with advanced age. We explored immuno-epidemiologic correlates of surveillance findings including humoral and cell-mediated immunity (CMI). METHODS: In an age-based design, ∼100 banked/residual sera per 10-year age stratum were assessed by hemagglutination inhibition (HI) and microneutralization (MN) assays for preexisting antibody to pH1N1 and recent seasonal H1N1 and H3N2 strains. In a separate birth cohort design defined by childhood influenza A/subtype priming (1919-1929: H1N1; 1945-1949: H1N1; 1958-1960: H2N2; 1969-1970: H3N2; 1978-1989: H3N2/H1N1), whole blood was collected from up to 50 volunteers per birth cohort. The ratio of Th1(IFN-γ):Th2(IL-10) cytokine responses was evaluated in vitro. RESULTS: Antibody to seasonal viruses was highest in school-age children. Cross-reactive HI/MN antibody to pH1N1 was low among participants <70 years of age (yoa; 6%/4% ≥ 40), but seroprevalence increased at 70-79 yoa (27%/6%), increased even more at 80-89 yoa (65%/47%), and was highest at ≥90 yoa (88%/76%). CMI to pH1N1 was evident in all 5 birth cohorts but was lower compared with seasonal strains. There was little differentiation by subtype priming, but the Th1:Th2 ratio for all viruses dropped significantly in the 2 oldest cohorts. CONCLUSIONS: Preexisting antibody may have protected the very old from pH1N1 infection, while diminished CMI may have contributed to greater severity once infected. In the young, cross-reactive pH1N1 antibody was mostly absent, while more intact CMI may have protected against severe outcomes.
Authors: Karlijn Gijzen; Wai Ming Liu; Ildikó Visontai; Fredrik Oftung; Sylvie van der Werf; Gro Ellen Korsvold; Inge Pronk; Ingeborg S Aaberge; Anna Tütto; Istvan Jankovics; Mate Jankovics; Beth Gentleman; Janet E McElhaney; Ernst C Soethout Journal: Vaccine Date: 2010-03-04 Impact factor: 3.641
Authors: Danuta M Skowronski; Gaston De Serres; Natasha S Crowcroft; Naveed Z Janjua; Nicole Boulianne; Travis S Hottes; Laura C Rosella; James A Dickinson; Rodica Gilca; Pam Sethi; Najwa Ouhoummane; Donald J Willison; Isabelle Rouleau; Martin Petric; Kevin Fonseca; Steven J Drews; Anuradha Rebbapragada; Hugues Charest; Marie-Eve Hamelin; Guy Boivin; Jennifer L Gardy; Yan Li; Trijntje L Kwindt; David M Patrick; Robert C Brunham Journal: PLoS Med Date: 2010-04-06 Impact factor: 11.069
Authors: Elizabeth Miller; Katja Hoschler; Pia Hardelid; Elaine Stanford; Nick Andrews; Maria Zambon Journal: Lancet Date: 2010-01-21 Impact factor: 79.321
Authors: Kathy Hancock; Vic Veguilla; Xiuhua Lu; Weimin Zhong; Eboneé N Butler; Hong Sun; Feng Liu; Libo Dong; Joshua R DeVos; Paul M Gargiullo; T Lynnette Brammer; Nancy J Cox; Terrence M Tumpey; Jacqueline M Katz Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: Tom Reichert; Gerardo Chowell; Hiroshi Nishiura; Ronald A Christensen; Jonathan A McCullers Journal: BMC Infect Dis Date: 2010-01-07 Impact factor: 3.090
Authors: Hayedeh Behzad; Anke L W Huckriede; Laura Haynes; Beth Gentleman; Krysta Coyle; Jan C Wilschut; Tobias R Kollmann; Steven G Reed; Janet E McElhaney Journal: J Infect Dis Date: 2011-12-05 Impact factor: 5.226
Authors: Danuta M Skowronski; Travis S Hottes; Naveed Z Janjua; Dale Purych; Suzana Sabaiduc; Tracy Chan; Gaston De Serres; Jennifer Gardy; Janet E McElhaney; David M Patrick; Martin Petric Journal: CMAJ Date: 2010-10-18 Impact factor: 8.262
Authors: A Ali; J B Daniels; Y Zhang; A Rodriguez-Palacios; K Hayes-Ozello; L Mathes; C-W Lee Journal: J Clin Microbiol Date: 2011-09-28 Impact factor: 5.948
Authors: Jennifer L Nguyen; Wan Yang; Kazuhiko Ito; Thomas D Matte; Jeffrey Shaman; Patrick L Kinney Journal: JAMA Cardiol Date: 2016-06-01 Impact factor: 14.676
Authors: Janet E McElhaney; Xin Zhou; H Keipp Talbot; Ernst Soethout; R Chris Bleackley; David J Granville; Graham Pawelec Journal: Vaccine Date: 2012-01-27 Impact factor: 3.641
Authors: Arun Kumar; Janet E McElhaney; Lisa Walrond; Terry D Cyr; Shahzma Merani; Tobias R Kollmann; Scott A Halperin; David W Scheifele Journal: Hum Vaccin Immunother Date: 2017-06-21 Impact factor: 3.452
Authors: Michael D Denkinger; Hanna Leins; Reinhold Schirmbeck; Maria Carolina Florian; Hartmut Geiger Journal: Trends Immunol Date: 2015-11-21 Impact factor: 16.687